Exploring the contribution of astrocytes to Huntington disease

探索星形胶质细胞对亨廷顿病的贡献

• 批准号: 10231078
• 负责人: Michelle Gray
• 金额: $ 44.95万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10231078
• 关键词: Adult; Affect; Astrocytes; Behavior; Behavioral; Brain; Cells; Clinical; Cognitive; Corpus striatum structure; D Cells; Data; Development; Disease; Disease Progression; Dopamine D1 Receptor; Dopamine D2 Receptor; Electrophysiology (science); Feedback; Frequencies; Functional disorder; GABA Transporter 1; GABA transporter; GAT3 transporter; Genetic study; Glial Fibrillary Acidic Protein; Glutamates; Goals; Hippocampus (Brain); Huntington Disease; Huntington gene; Huntington protein; Interneurons; Knowledge; Length; Modeling; Molecular; Movement; Mus; Mutate; Nerve Degeneration; Neurodegenerative Disorders; Neuroglia; Neurons; Parvalbumins; Pathway interactions; Patients; Phenotype; Play; Proteins; Risk; Role; Signal Transduction; Somatostatin; Synapses; Thalamic structure; Toxic effect; Viral; base; behavioral phenotyping; cell type; clinical Diagnosis; design; effective therapy; experimental study; extracellular; gamma-Aminobutyric Acid; hippocampal pyramidal neuron; inhibitory neuron; motor deficit; mutant; nervous system development; neurotransmission; optogenetics; overexpression; symptom treatment; uptake

Project Summary Huntington's disease (HD) is a fatal, progressive adult-onset autosomal dominant neurodegenerative disorder characterized clinically by cognitive, psychiatric and motor deficits. Degeneration of striatum medium spiny neurons (MSN) is the most prominent neuropathological change observed in HD. At present, there are no neuroprotective treatments for HD and symptomatic treatments are also largely ineffective. The mutated huntingtin (mHTT) protein is widely expressed in neuronal and non-neuronal cells, yet significant neurodegeneration is only observed for a subset of neurons in the brain. Understanding the toxicity produced by mHTT in a given cell type, the cellular interactions and underlying molecular changes in HD that contribute to the classic behavioral deficits and selective degeneration are likely to be critical in the design of effective therapies for the disease. One goal of this proposal is to expand our knowledge of the contribution of full length-mHTT (fl-mHTT) expressing astrocytes to deficits in striatal MSNs. Astrocytes are critical to the proper function and development of the nervous system. They modulate synaptic activity and neurotransmission. We have demonstrated that fl-mHTT expressing astrocytes in conditional fl-mHTT BACHD mice contribute to behavioral and neuropathological phenotypes observed in HD. Electrophysiological studies in BACHD mice revealed increased inhibitory input onto MSNs and a reduction of tonic inhibition in these neurons. There is increased spontaneous firing of striatal somatostatin GABAergic interneurons in the BACHD striatum. We found increased extracellular GABA (e[GABA]) in the striatum of 12 month old BACHD mice that is reduced with a decrease of mHTT expression in astrocytes. In protein extracted from the striatum of the 12 month old BACHD mice, we identified a decrease in GABA transporter 1, GAT1. The GAT1 transporter is responsible for uptake of e[GABA]. Recent studies revealed that astrocytes respond to activation of GABAergic somatostatin interneurons in the cortex through GAT3 and increases their inhibitory activity onto downstream pyramidal neurons. We hypothesize that deficits elicited by mHTT in somatostatin interneurons and astrocytes interact to contribute to the increased GABAergic inhibitory activity onto MSNs. We have designed experiments to assess the contribution of mHTT expressing astrocytes to the increased inhibition and reduced tonic conduction of MSNs. Furthermore, we will provide the first assessment of the role fl-mHTT expressing somatostatin interneurons play in the development of the electrophysiological changes in medium spiny neurons and the HD-like phenotypes in the BACHD mice. We will also assess whether overexpression of GABA transporters in the striatum decreases the electrophysiological deficits and e[GABA] observed in MSNs in the BACHD mice.

项目摘要 亨廷顿病（Huntington 'sDisease，HD）是一种致死性、进行性的成人常染色体显性遗传性神经退行性疾病 临床上表现为认知、精神和运动缺陷。纹状体中棘变性 神经元（MSN）是HD中观察到的最突出的神经病理学变化。目前没有 HD的神经保护治疗和对症治疗也基本无效。突变的 亨廷顿蛋白（mHTT）在神经元和非神经元细胞中广泛表达，但其在神经元和非神经元细胞中具有显著的生物学活性。 仅在脑中的一部分神经元中观察到神经变性。了解所产生的毒性 通过mHTT在给定的细胞类型，细胞相互作用和潜在的分子变化，在HD，有助于 经典的行为缺陷和选择性变性可能是设计有效的 该疾病的治疗方法。 该建议的一个目标是扩大我们对全长-mHTT（fl-mHTT）贡献的认识 表达星形胶质细胞以减少纹状体MSN中的缺陷。星形胶质细胞对正常功能至关重要， 神经系统的发育。它们调节突触活动和神经传递。我们有 结果表明，条件fl-mHTT BACHD小鼠中表达fl-mHTT的星形胶质细胞有助于行为 和HD中观察到的神经病理表型。 BACHD小鼠的电生理学研究显示，MSNs的抑制性输入增加， 这些神经元的紧张性抑制减少。纹状体生长抑素自发放电增加 BACHD纹状体中的GABA能中间神经元。我们发现，增加细胞外GABA（e[GABA]）在 在12个月大的BACHD小鼠的纹状体中，随着星形胶质细胞中mHTT表达的减少而减少。在 从12个月大的BACHD小鼠的纹状体中提取的蛋白质，我们鉴定出GABA减少， 转运蛋白1 GAT 1 GAT 1转运蛋白负责摄取e[GABA]。 最近的研究表明星形胶质细胞对GABA能生长抑素中间神经元的激活有反应 通过GAT 3在皮质中的作用，并增加其对下游锥体神经元的抑制活性。我们 假设mHTT引起生长抑素中间神经元和星形胶质细胞相互作用， 对MSN的GABA能抑制活性增加。我们设计了实验来评估 表达mHTT的星形胶质细胞对MSN的抑制增加和紧张性传导减少的贡献。 此外，我们将提供fl-mHTT表达生长抑素中间神经元的作用的第一个评估， 在中棘神经元和HD样神经元电生理变化的发展中起作用 BACHD小鼠中的表型。我们还将评估GABA转运蛋白在脑组织中的过度表达， 纹状体减少BACHD小鼠MSN中观察到的电生理缺陷和e[GABA]。